BioCentury | Jan 9, 2020
Product Development

Pfizer dips into translational regulation for cancer with eFFECTOR deal

eFFECTOR’s deal with Pfizer is the latest indication that translational control elements are a promising, emerging source of new drug targets. The companies teamed up to develop small molecule inhibitors of the translation initiation complex...
BC Innovations | May 24, 2019
Emerging Company Profile

Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg...
BC Week In Review | Feb 2, 2018
Clinical News

Effector reports Phase I/II data for eFT508 in hematological malignancies

Effector Therapeutics Inc. (San Diego, Calif.) reported data from 10 evaluable patients with hematological malignancies in a Phase I/II trial showing that eFT508 led to one partial response in a patient with non-germinal center B...
BioCentury | Dec 9, 2017
Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
BC Week In Review | Nov 3, 2017
Clinical News

Effector begins Phase II trial of eFT508 plus Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) began a Phase II trial of eFT508 with or without PD-L1 inhibitor Bavencio avelumab (MSB0010718C, PF-06834635) to treat microsatellite stable colorectal cancer (CRC). Part one of the open-label, U.S....
BC Innovations | Aug 9, 2017
Distillery Therapeutics

Neurology

INDICATION: Pain Mouse studies suggest inhibiting the MKNK1 - MKNK2 - eIF4E axis could help treat pain. In a mouse model of inflammatory pain, knock-in of an elF4E variant that cannot be phosphorylated by MKNK1 or MKNK2...
BioCentury | Jul 29, 2017
Finance

Potentiator potential

Preclinical data showing how eFT508 could fit into checkpoint inhibitor cocktails helped Effector Therapeutics Inc. snag Pfizer Inc. (NYSE:PFE) as both a development partner and an investor. On July 24, Effector closed a $19.3 million...
BC Extra | Jul 24, 2017
Financial News

Effector raises $38.6M in series C

Cancer company Effector Therapeutics Inc. (San Diego, Calif.) raised $38.6 million in a series C round led by new investor Pfizer Venture Investments. Also participating were new investor Alexandria Venture Investments and existing investors U.S....
BC Week In Review | Jul 7, 2017
Company News

Effector combining EFT508 and Bavencio

Effector Therapeutics Inc. (San Diego, Calif.) will conduct an open-label, Phase II trial evaluating EFT508 with or without PD-L1 inhibitor Bavencio avelumab from Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) in patients with microsatellite stable...
BioCentury | Aug 15, 2016
Emerging Company Profile

Restraining translation

Bantam Pharmaceutical LLC is developing small molecule eukaryotic translation initiation factor 4E inhibitors that selectively inhibit translation of several tumor-promoting genes and disrupt cancer cell metabolism. It hopes to show the mechanism of its lead...
Items per page:
1 - 10 of 19